Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Dec 30;15(12):e0244306. doi: 10.1371/journal.pone.0244306

Microbiological profile of diabetic foot ulcers in Kuwait

Asma Alhubail 1, May Sewify 1, Grace Messenger 1, Richard Masoetsa 1, Imtiaz Hussain 1, Shinu Nair 1, Ali Tiss 2,*
Editor: Rita G Sobral3
PMCID: PMC7773204  PMID: 33378365

Abstract

Introduction

Diabetic foot ulcers (DFU) and infection (DFI) are a major diabetes-related problem around the world due to the high prevalence of diabetes in the population. The aim of our study was to determine the microbiological profile of infected ulcers in patients attending Dasman Diabetes Institute (DDI) clinics in Kuwait and to analyze the distribution of microbial isolates according to wound grade, sex, age and diabetes control.

Methods

We collected and analyzed clinical data and samples from 513 diabetic patients with foot ulcers referred to our podiatry clinic at DDI from Jan 2011 till Dec 2017.

Results

We show a higher prevalence of DFU in men than in women, and a greater percentage of DFU occurred in men at an earlier age (p<0.05). Only about half of the DFU were clinically infected (49.3%) but 92% of DFU showed bacterial growth in the microbiological lab analysis. In addition, we isolated more monomicrobial (57.3%) than polymicrobial (34.8%) DFI and representing an average of 1.30 pathogens per patient. The presence of Gram-positive and Gram-negative strains was comparable between men and women regardless their age or glucose levels. Interestingly, more Gram-positive strains are present in ulcers without ischemia while more Gram-negative strains are present in ulcers with ischemia (p<0.05). While Staphylococcus aureus was common in infected ulcers without ischemia, Pseudomonas aeruginosa was predominant in ulcers with infection and ischemia, regardless of ulcer depth. Finally, a higher percentage of women has controlled HbA1c levels (19.41% versus 11.95% in men) and more women in this group displayed non-infected wounds (60.6% and 43.90% for women and men, respectively).

Conclusion

Our results provide an updated picture of the DFI patterns and antibiotics resistance in patients attending Dasman Diabetes Institute (DDI) clinics in Kuwait which might help in adopting the appropriate treatment of infected foot and improving clinical outcomes.

1 Introduction

Diabetic foot ulcers (DFU) are one of the commonest long-term complications of diabetes mellitus. The lifetime risk of developing a DFU in diabetic patients is estimated to be 12 to 25% [13]. According to the “Diabetic Foot Ulcers-Epidemiology Forecast to 2025,” which includes data from seven countries, over 1 million foot-ulceration cases were reported in 2015, and the estimated increasing rate is higher than 4% per year in those countries [4]. Despite the fact that the prevalence of diabetes in Kuwait (22.0%) is ranked among the top 20 highest worldwide [5], a single centered study conducted in Kuwait reported an incidence of 3.4% for DFU [6]. The etiology of DFU is multi-factorial with the triad of diabetic peripheral neuropathy, peripheral arterial disease, and foot deformity responsible for the majority of DFU. Another major contributing factor to DFU outcomes is diabetic foot infection (DFI), which has been found to be present in 40–60% of all DFU [7, 8], and is associated with increased hospital admissions, worsening outcomes, and increased amputation rates [9, 10].

Clinically, DFI is said to be present if there are two or more cardinal signs of inflammation (induration, erythema, raised temperature, increased pain, and purulent discharge) [9]. DFI can be categorized as mild, moderate, or severe and are frequently polymicrobial, with multiple bacteria identified in them [9, 11]. Gram-positive bacteria, such as Staphylococcus aureus, and Gram-negative bacteria, such as Pseudomonas aeruginosa, are the most common pathogens [9]. However, the incidence and the prevalence of Methicillin Resistant Staphylococcus aureus (MRSA) have both increased, which has been associated with improper antibiotic use and non-restrictive regulations controlling antibiotic abuse [12].

The diversity of bacteria in chronic wounds is considered an important contributor to the chronicity and severity of DFU [11], and the polymicrobial nature of DFI has been well studied [9, 1315]. However, results were variable. Studies have found that Staphylococcus aureus is the main causative pathogen [1618], but others have reported a predominance of Gram-negative aerobes [19, 20]. These discrepancies could be related to various factors, such as the presence of different causative organisms at different times, geographical variations and ecologies, socio-economic conditions, hygiene, accessibility to effective health care services, the type and the severity of the infections, or depth of the wound and sampling technique [14, 21]. These differences in microbial pathogens have triggered considerable efforts to decipher their impact on DFI and improve treatment outcomes [22]. Consequently, studies have shown that parenteral and oral antibiotic treatment, guided by culture, successfully prevent amputations in a large proportion of patients with diabetes admitted with a DFU or suspected osteomyelitis [23].

In order to obtain the evidence necessary to enhance the effectiveness of DFI treatments in Kuwait, we aimed to: (i) profile and compare the microbes isolated from DFI from different ulcer grades using the University of Texas Wound Classification and combine these findings with antimicrobial sensitivity (ii) identify the most frequent DFI pathogens within our geographical region (iii) determine if the microbial profile of DFI differ according to patients age, diabetes control and sex. We retrospectively analyzed clinical data and microbiological samples collected from 513 patients with DFU treated at the Podiatry Department at the Dasman Diabetes Institute (DDI) in Kuwait for a period of 7 years.

2 Materials and methods

2.1 Study population

We collected data for this study from electronic health records at the Podiatry department, Dasman Diabetes Institute (DDI) from January 2011 to December 2017. DDI is a specialized outpatient center helping patients with diabetes mellitus manage their blood glucose levels and treat diabetes complications. Diabetic patients with complications were referred to DDI from all governorates in Kuwait and might be considered representative of all Kuwait population. During this period, 835 patients with DFU were referred to the Podiatry department, this represented around 120 patients per year. Microbiology samples were taken from 513 patients within this cohort at their first visit to our podiatry services. We obtained information on patients’ age, sex, diabetes control, and treatment history of diabetes from the DDI Laboratory Information System (LIS) and the main parameters are summarized in Table 1. Approval and a waiver from the need to provide written informed consent were obtained from The Ethical Review Board of DDI for the access and use of anonymized data from the LIS for the purpose of publication.

Table 1. Study population characteristics.

Diabetes Status Parameter Sex Total
Male Female
Controlled (HbA1c<6.5%) N = 41 33 74
(11.95%) a (19.41%) b (14.42%) c
age (years) 60 ± 12 64 ± 9 62 ± 11
Uncontrolled (HbA1c ≥6.5%) N = 302 137 439
(88.05%) a (80.59%) b (85.58%) c
Age (years) 61 ± 11 65 ± 10 62 ± 11
Total N = 343 170 513
(66.86%) c (33.14%) c
Age (years) 61 ± 11 65 ± 10 * 62 ± 11

*: p<0.05 between sexes.

a (% from all Males)

b (% from all Females)

c (% from all population)

2.2 Wound grading

Our experienced podiatrists classified the DFU according to the University of Texas Wound (UoT) Grading Classification System which grades DFU by depth (0, I, II, III) and stage (A, B, C, D) depending on the presence or absence of infection and ischemia [24]. This comprehensive and validated classification tool was consistently used for all subjects to develop a management plan and determine the eventual outcome of the DFU which are known to deteriorate with increased stages and grades. Clinical diagnosis of infection which has previously been defined [9, 23] by the presence of at least 2 of the following indicators: local swelling or induration, >0.5 cm of erythema around the wound, local tenderness or pain, local warmth, and purulent discharge was used.

2.3 Samples collection and processing

Samples were taken by the podiatry staff at the patient’s first appointment as per DDI policy at the time, or when there was clinical suspicion of DFI. Prior to sample collection the DFU was cleansed with sterile saline solution, and sharp debrided. Samples were collected either using a surface swab or wound biopsy. Surface swabs were collected using Levine’s Technique [25], involving the rotation of a wound swab over a 1 cm2 area of the wound for 5 seconds, using sufficient pressure to extract fluid from the inner part of the wound. Deep tissue specimens of 4mm in diameter were obtained from the base of the ulcer during the sharp debridement process. The specimens were placed into sterile transport containers and sent to the microbiology laboratory for aerobic culturing within 20 minutes. Anaerobic culturing was not performed in this study.

Different types of media were used for sample inoculations; namely, blood, MacConkey, chocolate, mannitol-salt (MSA), Sabouraud agars, and thioglycolate broth (Oxoid, Basingstoke, UK). All plates were incubated for a maximum of five days or until visible growth using aerobic (O2) at 37°C, which ever come first; except for MRSA plates, which were incubated at 32°C. Cultures with any volume of bacterial growth present on at least one of the inoculated plates was reported as laboratory positive. We did not consider lower or upper bacterial growth limits when reporting the presence of bacterial growth.

2.4 Identification of isolated microorganisms

All microbiological analyses were performed in our College of American Pathologist- (CAP) accredited Clinical lab at DDI (CAP Lab #8086466). Cultures were processed following the same CAP approved standard procedures for both swab and tissue samples and identification was done according to the Clinical & Laboratory Standards Institute (CLSI -M50 and CLSI-M100). All plates were examined for visible growth after 24 hours of incubation. Subcultures for thioglycolated broth tubes were done after a 24-hour incubation period, using blood, MacConkey, and Sabouraud agar plates. Wound smears from each sample were Gram-stained to identify if Gram-positive or Gram-negative isolates were present. We considered no-growth plates as sterile after five days of incubation. For positive swab or tissue cultures, we performed identifications using an automated Microscan system (Walkaway 40 SI, Siemens Healthcare Diagnostics, and Sacramento, CA). We obtained panels for Gram-negative (NC34, NC50 and NC53) and for Gram-positive bacteria (PC21, PC39) from Siemens Healthcare Diagnostics (Sacramento, CA). For confirmation, we performed further biochemical tests for both Gram-positive and Gram-negative isolates using commercially available reagents (API 20E, API strep, and API staph) supplied by BioMérieux (Durham, NC, USA). MRSA confirmation was done at the Faculty of Medicine services, Kuwait University, by DNA sequencing (MicoSeq) of the isolates. Quality control strains (Escherichia coli ATCC® 25922, Klebsiella pneumonia ATCC® 700603, Candida albicans ATCC® 10231, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212) were supplied by the American Type Culture Collection (ATCC) (Manassas, VA).

2.5 Antimicrobial susceptibility testing

Susceptibilities to selected antibiotics for the common isolated bacteria (Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter sp and Enterobacter sp) were examined. Antimicrobial sensitivity testing of all isolates was performed on diagnostic sensitivity test plates according to the Kirby-Bauer method [26] following the definition of the Clinical and Laboratory Standards Institute (CLSI, 2014). Antibiotics and their concentrations used for antimicrobial susceptibility testing, are as following: Amikacin 30ug, Ampicillin10ug, Co-Amoxi/clav30 ug, Ceftazidime 30ug, Ciprofloxacin 5ug, Clindamycin 2ug, Ceftriaxone 30ug, Cefotaxime 30ug, Erythromycin 15ug, Gentamicin 10ug, Imipenem 10ug, Linezolid 30ug, Meropenem 10ug, Piperacillin/Tazobactam 110ug, Trimethoprim-Sulfamethoxazole 25ug, and Vancomycin 30ug. Bacterial inoculums were prepared by suspending the freshly grown bacteria in 5mL sterile saline solution. A sterile cotton swab was used to streak the surface of Mueller Hinton agar plates (Oxoid, Basingstoke, UK). Filter paper disks containing a designated concentration of the antimicrobial drugs obtained from Becton and Dickinson Company (Franklin Lakes, NJ) were used.

2.6 Statistical analysis

We analyzed the data using the statistical SPSS software, v22.0 (IBM SPSS Statistics for Windows, IBM Corp. Armonk, NY, USA). We evaluated differences between continuous and categorical variables using the Student’s t-test and the chi-square with F-test, respectively. We calculated correlations between variables with the Spearman’s rank correlation test. All statistical assessments were two sided and considered significant at p values <0.05.

3 Results

3.1 Study population characteristics

During the study period, 513 patients attended the Podiatry Department at DDI with a diabetic foot ulcer which underwent laboratory investigation following swab or tissue sample collection. The mean age of patients was 62 ± 11 years (95% CI, 61.7–63.5), with a mean HbA1c of 8.6 ± 1.9% (95% CI, 8.4–8.8, equivalent to 70mmol/mol). The study group contained twice as many men as women (66.9% vs. 33.1%, respectively), with a statistically significant difference in the mean age between sexes (61 ± 11; 95% CI, 60.5–62.8 in men and 65 ± 10; 95% CI, 63.1–66.3 in women; p < 0.001,). However, we found no significant difference in mean HbA1c values between sexes (8.7± 1.9%; 95% CI, 8.5–8.9 for men and 8.4 ± 1.9%; 95% CI 8.1–8.7 for women; p = 0.178). In our study population, 85.6% of patients had uncontrolled HbA1c levels (≥6.5% or 48 mmol/mol), among them 22.8% had HbA1c ≥10% (equivalent to 86 mmol/mol) (Table 1). When dividing data according to HbA1c levels, we found more women (19.41%) than men (11.95%) with controlled HbA1c levels (p = 0.024).

Using the University of Texas (UoT) Wound Classification System, during the podiatry appointment, at the time of sample collection, we classified 253 (49.3%) DFU as clinically infected. This included 30.4% as UoT grade B (infection only) and 18.9% as UoT grade D (infection and ischemia) from the total study population. The remaining 260 patients (50.7%) had no clinical signs or symptoms of infection, including 42.5% as grade A and only 8.2% as grade C (Table 2). Within the whole study population just over one-quarter (27.1%) of ulcers were complicated with ischaemia, of which 69.7% also had infection. There was no difference in sex between the two groups, with neither sex being more likely to present with an infected ulcers than the other (49.6% and 48.8% of males and female, respectively; p = 0.642) (Table 2 & Fig 1A). Similarly, there was no difference in means between age (p = 0.650) or HbA1c (p = 0.310). In addition, when splitting the two groups depending on their controlled and uncontrolled HbA1c levels, no significant difference was observed between the groups (Fig 1A & 1B). Nevertheless, there was significantly more males with deeper and more complex DFU than females (ꭓ2(2) = 6.135; p = 0.047). Interestingly, there was a significant difference between the mean age and ulcer classification; patients with infected ulcers were approximately 5 years younger than patients with infection and ischemia (60.3±10.7 and 65.9±13.4 respectively, p <0.001). Additionally, this trend was continued when we took into consideration depth of DFU (p = 0.002).

Table 2. Texas wound grading distribution among the study population.

HBA1c Total
Sex Controlled (<6.5%) Uncontrolled (≥6.5%)
Texas wound grads A&C male 18 155 173
(no infection ± ischemia) female 20 67 87
(Control Group) Total 38 222 260
Texas wound grads B&D male 23 147 170
(infection ± ischemia) female 13 70 83
Total 36 217 253
Total 74 439 513

Fig 1. Wound grading distribution among the DFU study population.

Fig 1

Patient DFU were classified according to the University of Texas Wound Grading Classification System which grades them depending on the presence or absence of infection and ischemia, as detailed in Material and Methods section.

There were 207 clinically uninfected (Grade A & C) and 196 clinically infected (Grade B & D) DFU with HbA1c levels below 10.0% and 53 uninfected and 57 infected FDUs with HbA1c greater than 10.0%. However, there was no significant difference in the distribution of HbA1c levels between infected and uninfected DFU classification (p = 0.455) (Table 2). Using Chi-square analysis, no significant association was observed between diabetes control and the presence of infection (ꭓ2(2) = 0.3503; p = 0.554). Nevertheless, when we grouped the infected and uninfected DFU by UoT depth, a significant difference in mean HbA1c was found (F(5, 246) = 2.584, p = 0.027). Nearly 51% of DFU in our patients had no clinical signs of infection and were graded as UoT A or C. Interestingly, 47.7% of grade A and 42.9% of grade C DFU grew at least one of the following bacteria, Methicillin Sensitive Staphylococcus aureus (MSSA), MRSA, and Pseudomonas aeruginosa (data not shown).

3.2 Microbial isolate etiologies in ulcers with clinical infection

To better characterize the microbial etiology related to DFI, in the remaining part of our study and analyses we only included the clinically infected wounds (n = 253). Tables 3 and 4 summarize the distribution of microorganism isolates among the study population with clinical infection. Ninety-two percent of all samples collected grew one or more isolates. In these patients with infected ulcers, the mean age was significantly higher in those without growth (66.4 ± 9.2; CI, 63.6–69.3 years) than those with bacterial growth (61.3 ± 10.9; CI, 60.3–63.3 years); t(53.2) = −2.96, p = 0.005. However, we found no such significance in sex or HbA1c between those two groups (p = 0.108). Most microbiological samples were monomicrobial (57.3%), followed by polymicrobial (34.8%) and no growth (7.9%). No significant association between sex or diabetes control and number of isolates (p = 0.08 and p = 0.403, respectively) was found.

Table 3. Distribution of microorganisms isolated from various samples used in the study.

Isolates Name Wound swab Culture Tissue Culture Bone Culture Total (% of frequency)
Staphylococcus aureus 116 7 2 125 (17.9%)
Coagulase negative Staphylococcus sp 117 12 1 130 (18.5%)
Pseudomonas aeruginosa 80 15 7 102 (14.6%)
Klebsiella sp 45 8 4 57 (8.1%)
Citrobacter sp 14 0 1 15 (2.14%)
Enterobacter sp 45 6 1 52 (7.4%)
Streptococcus sp 27 4 0 31 (4.4%)
Candida albicans 4 0 0 4 (0.6%)
Morgenella sp 20 0 0 20 (2.9%)
Protues sp 29 1 1 31 (4.4%)
Acinitobacter sp 14 0 0 14 (2.0%)
Serratia sp 5 0 0 5 (0.71%)
Achromobacter xylosoxidans 1 0 0 1 (0.14%)
Ochrobacterium anthropi 1 0 0 1 (0.14%)
Escherichia coli 36 5 2 43 (6.1%)
Enterococcus faecalis 20 1 0 21 (3%)
MRSA 44 3 0 47 (6.7%)
Total 618 62 19 699

Table 4. Microorganism isolates distribution among the study population with clinically infected wounds.

Isolate name B1 B2 B3 Total B D1 D2 D3 Total D Total
Staphylococcus aureus 29 3 5 37 (66.1%) 8 1 10 19 (33.9%) 56 (19.9%)
Coagulase negative staphylococcus 24 1 8 33 (75%) 7 0 4 11 (25%) 44 (15.7%)
Streptococcus sp 6 2 5 13 (81.3%) 0 1 2 3 (18.7%) 16 (5.7%)
Enterococcus fecalis 1 1 4 6 (50.0%) 0 0 6 6 (50.0%) 12 (4.3%)
MRSA 3 2 7 12 (85.7%) 0 0 2 2 (14.3%) 14 (5.0%)
Pseudomonas aeruginosa 5 2 7 14 (38.9%) 7 3 12 22 (61.1%) 36 (12.8%)
Klebsiella sp 6 3 0 9 (39.1%) 7 2 5 14 (60.9%) 23 (8.2%)
Citrobacter sp 5 0 1 6 (75.0%) 0 1 1 2 (25%) 8 (2.8%)
Acinetobacter sp 3 0 2 5 (100%) 0 0 0 0 5 (1.8%)
Enterobacter sp 5 1 6 12 (54.5%) 2 1 7 10 (45.5%) 22 (7.8%)
Morgenella sp 2 1 1 4 (57.1%) 2 0 1 3 (42.9%) 7 (2.5%)
Proteus spp 4 0 5 9 (60.0%) 1 1 1 3 (40.0%) 12 (4.3%)
Serratia spp 0 0 0 0 0 0 1 1 (100%) 1 (0.3%)
Achromobacter xylosoxidans 1 0 0 1 (100%) 0 0 0 0 1 (0.3%)
Ochrobactrum anthropi 0 0 1 1 (100%) 0 0 0 0 1 (0.3%)
Escherichia coli 5 0 4 9 (45.0%) 4 2 5 11 (55.0%) 20 (7.1%)
Candida albicans 0 0 0 0 0 1 2 3 (100%) 3 (1.0%)
Total 99 16 56 171 38 13 59 110 281

The presence of Gram-positive and Gram-negative strains was comparable (50.5% -including 5.0% MRSA- and 48.4%, respectively), while yeast was present only in 1.1% of cultures (Table 4). There was no significant association between sex and Gram type (p = 0.801). Significant trends were, however, observed between DFU depth and bacteria groups. For instance, superficial infected ulcers not involving tendon, capsule or bone and DFU penetrating to tendon or capsule were more likely to be infected by gram positive bacteria than those of the same depth and complicated by the presence of infection and ischemia (χ2 = 5.65 (df2), p = 0.0175 and χ2 (2)23.376, p <0.001, respectively). As shown in Table 4, most Gram-positive isolates were Staphylococcus aureus (19.9%), coagulase-negative Staphylococcus aureus (15.7%), Streptococcus spp. (5.7%), MRSA (5.0%) and Enterococcus faecalis (4.3%). Within the Gram-negative isolates, the spectrum of strains was larger, and the main isolates were Pseudomonas aeruginosa (12.8%), Klebsiella species (8.2%), Enterobacter species (7.8%), Escherichia coli (7.1%) and Proteus spp. (4.3%).

We further analyzed the number of isolates present in those ulcers with clinical infection but different depths (I, II, III), however, no association was found between these parameters (χ2(7) = 6.27; p = 0.180). In contrast, Staphylococcus aureus and MRSA were predominantly found in infected ulcers while Pseudomonas aeruginosa was predominantly found in ulcers with infection and ischemia as reflected by the number of patients in each of the DFU grades (Table 4) and the relative distribution of these 3 strains within each of those grades (Fig 2) (p<0.05). Indeed, Staphylococcus aureus and MRSA were isolated from 66.1% and 85.7% of infected ulcers as compared to 33.9% and 14.3% respectively in DFU with infection and ischemia, respectively, whereas Pseudomonas aeruginosa was present 61.1% of DFU with infection and ischemia compared to only 38.9% in infected ulcers (Table 4). In the next step, we analyzed the potential association between bacterial strain and depth (I, II, III). DFU penetrating to bone or joint (BIII or DIII) had a higher proportion of MRSA in comparison to DFU with less depth, however, the limited number of samples in some sub-groups did not allow us to draw a clear conclusion on the association of bacterial strains within DFU subgrades (Fig 2).

Fig 2. Main species distribution among the study population with clinically infected wounds.

Fig 2

The species distribution was calculated as percentage of the total number of isolates within the same wound grade.

3.3 Antimicrobial susceptibility pattern

The most prevalent gram-negative and gram-positive pathogens isolated from our DFI patients were tested for their sensitivity against a wide range of antibiotics and results are shown in Table 5. Staphylococcus aureus showed low resistance to vancomycin and linezolid (0% and 2.5%, respectively) but was more resistant to other tested antibiotics (53.6% and 83% for erythromycin and ampicillin, respectively). Of the gram-negative isolates, Pseudomonas aeruginosa was relatively less resistant to meropenem, amikacin, imipenem, gentamicin, and ciprofloxacin (11.6%, 13%, 15%, 20% and 22.8%, respectively). Meanwhile, Escherichia coli strains were not resistant or showing very low resistance to imipenem, meropenem, amikacin, piperacillin/ tazobactam and gentamicin (0%, 0%, 0%, 0% and 2.7%, respectively). Klebsiella species were not or barely resistant to imipenem, meropenem, piperacillin/tazobactam, and gentamicin (0%, 0%, 7% and 9%, respectively). Finally, Acinetobacter and Enterobacter species were resistant to ceftriaxone (66.7−68.2%) while being moderately to highly sensitive to the other antibiotics (Table 5).

Table 5. Antibiogram sensitivity pattern for most prevalent isolates.

Table 5a: Gram positive isolates
Organism Isolated AMC AMP ERY DA VA CIP GM LZ
Staphylococcus aureus 64% 17% 46.4% 56.6% 100% 73% 78% 97.5%
Table 5b: Gram positive isolates
Organism Isolated AMC AMP AK SXT CRO CTX CIP CAZ TZP GM MEM IMP
Pseudomonas aeruginosa - - 87% - - - 77.2% 65.7% 71.1% 80% 88.4% 85%
Klebsiella pneumonia 60% - 88.6% 61% 65.8% 63.6% 77.2% 63.6% 93% 91% 100% 100%
Escherichia coli 56% 19.4% 100% 39.4% 48.6% 68.4% 63.2% 73.6% 100% 97.3% 100% 100%
Acinetobacter sp - - 100% 91.6% 33.3% 33.3% 61.5% 75% 83.3% 92.3% 100% 100%
Enterobacter sp - - 94.5% 89% 31.8% 60% 85.2% 63.1% 76.3% 94.5 96.3% 96.3%

AK: Amikacin; AMP: Ampicillin; AMC: Co-Amoxiclav; CAZ: Ceftazidime; CIP: Ciprofloxacin; DA: Clindamycin; CRO: Ceftriaxone; CTX: Cefotaxime; ERY: Erythromycin; GM: Gentamicin; IMP: Imipenem; LZ: Linezolid; MEM: Meropenem; TZP: Piperacillin/ Tazobactam; SXT; Trimethoprim-Sulfamethoxazole; VA: Vancomycin

4 Discussion

DFU is expected to become a major diabetes-associated problem in Kuwait, as in many other countries, due to the high prevalence of diabetes in the population. However, only limited data on the subject is available in the country [13, 15]. In this paper, we report estimates of DFU classification and types of DFU infection from our diabetes-dedicated institute for a period of 7 years. Our main findings were: (i) DFU was twice more likely in men than in women in our clinics, and more often present in younger men than in women; (ii) despite being younger, more males present with deeper and complex DFU than females; (iii) only about half of the DFU were clinically infected (49.3%) but 92% of DFU showed bacterial growth in the microbiological lab analysis; (iv) comparable global findings of Gram-positive and Gram-negative strains, but significantly more Gram-positive strains are present in DFU without ischemia while more Gram-negative strains are present in DFU with ischemia; and (v) while Staphylococcus aureus was common in infected DFU without ischemia, Pseudomonas aeruginosa was more predominant in DFU with infection and ischemia, regardless of ulcer depth.

Our study population contained twice as many men as women with DFI, yet, our clinics have equal access to both sexes. This may be partially explained by a previous report which found that male sex and poor glycemic control are independent risk factors for DFI [27]. Similar trends have been observed in other countries, and authors have suggested that men are more likely to work outdoor which ultimately increases the risk to foot trauma and injury [28]. In addition, DFU were more often present in younger men than in women and despite being younger, more males presented with deeper and more complex DFU than females. Furthermore, we have observed an increased percentage of DFI in men at earlier ages than in women even without reaching statistical significance. This may be explained by the tendency of women to take more responsibility for medical care and personal hygiene, even though other factors cannot be ruled out. This hypothesis is further supported by our observations that (i) a higher percentage of women was present in the controlled HbA1c group (19.41% versus 11.95% in men) and (ii) more women in the controlled HbA1c group displayed non-infected wounds; grades A and C (43.90% and 60.6% for men and women, respectively) (Table 2 and Fig 1A).

Globally, the number of isolates found in DFI varies widely. Polymicrobial infection rates have been found to be more prevalent in studies from a number of different countries including 83.7% in Portugal [29], 60% in South India [19], 55.7% in Mumbai, India [30], and 40% in Italy [31], whereas others have reported higher rates of monomicrobial infections [32, 33]. Nevertheless, this variation in prevalence could be also related to sampling and processing techniques in each study. Overall, we found a higher percentage of DFI with monomicrobial isolates (57.3%) compared to polymicrobial isolates (34.8%) (1.30 pathogens per patient on average) and 8.2% with no growth. After excluding the no-growth samples, the average pathogens per patient increased to 1.43. Conversely, in Kuwait, two older hospital-based studies have reported high rates of polymicrobial infection (75% and 64%) in studies including 440 [15] and 86 [13] patients with DFI. This shift in number of isolates may be attributed to changes in DFU management, through regular follow-up and better patient education and knowledge throughout the country in the recent year. In Addition, DFI microbial etiology can change due to variations in healthcare systems and standard protocols as well as ethnicity and health status of the patients studied. In our study, and in agreement with a previous report from a teaching hospital in Kuwait [15], both Gram-positive and Gram-negative pathogens were similarly frequent in clinically infected DFU and no difference was observed in this pattern between sexes.

In the initial microbiological analysis of our DFI patients, we included both those with and without clinical infection as per the practices we had at the time in our institute. About half did not present with clinical signs of infection, these findings are similar to a previous large multicenter study of 1229 new DFU which reported an infection rate of 58% [34]. When performing microbiology culture analysis in our non-clinically infected patients, around 45% showed bacterial growth including at least one of the following bacteria, Staphylococcus aureus, MRSA, and Pseudomonas aeruginosa. Nevertheless, this bacterial presence was considered as colonization rather than infection. It is worth noting that following our current study and other unpublished data, the procedure has changed in our institute and now cultures are only collected from DFU with clinical signs of infection. This change in procedure is expected to reduce the costs involved in the management of DFU.

Interestingly, in our current analysis we found a significant trend between DFU depth and bacteria groups, where superficial infected DFU not involving tendon, capsule or bone and DFU penetrating to tendon or capsule were more likely to be infected by Gram-positive bacteria than those of the same depth and further complicated by the presence of ischemia. Accordingly, Staphylococcus aureus and MRSA were predominantly found in grades B while Pseudomonas aeruginosa was predominant in grade D wounds with underlying peripheral arterial disease. No association was, however, found between the number of isolates present and the DFU grade. We further assessed the potential association between DFU depth and the type of pathogens. However, even though DFU penetrating to bone and joint had a higher proportion of MRSA in comparison to wounds with less depth, the limited number of samples in some sub-groups did not allow us to draw a clear conclusion on this key question. In this context, different bacterial profiles have been reported with different wound grades, in which aggravated wounds and infections were associated with increased Gram-negative species, especially Pseudomonas aeruginosa [35]. However, debate remains open regarding the impact of polymicrobial infections on wound severity, as they have been reported to be more common in moderate wounds [35], while other reports suggest that polymicrobial infection increased in line with wound grading [36]. In a follow-up study over 10 weeks, Gardiner et al. examined DFI microbiome and found that it differed significantly and had a reduced diversity compared to that of control non-DFU wounds, and that this difference was not driven by the most abundant members of the wound pathogen community [37]. Those results and others, including our own, highlight the need for further detailed and goal-oriented designed studies to establish the potential association between strains and DFU grading before translating these debatable findings to clinical practice.

The observation that Staphylococcus aureus is the most common pathogen (19.9% excluding 5.0% MRSA) in our DFU patients followed by coagulase-negative Staphylococcus (15.7%) is concordant with most previous studies, including those from Kuwait, which also reported a high frequency of Staphylococcus aureus in DFI. This latter species causes the majority of human infections and has proven to be among the most persistent pathogens in healthcare facilities worldwide [38]. The MRSA rate in study is also comparable to the range reported in other countries, although prevalence rates vary widely [39, 40]. The reduction in polymicrobial infections in our study, in comparison to previous reports from Kuwait [13, 15], may reflect an improvement of healthcare system and in patients’ hygiene. However, we cannot rule out other potential reasons affecting this rate, such as the younger age of our studied population. It is noteworthy that in our study 2.5% of Staphylococcus aureus isolates have shown resistance to Linezolid. Despite most of Staphylococcus aureus isolates including MRSA, are susceptible to linezolid, the emergence of linezolid-resistant MRSA has been, however, previously reported [41, 42]. While E. coli and Klebsiella species were 100% sensitive to Carbapenems, Pseudomonas aeruginosa was relatively less sensitive to this class of antibiotics (88.4% and 85% sensitivity, respectively to Meropenem and Imipenem). These results are comparable to a previous report from Kuwait educational hospital where Pseudomonas aeruginosa was 10% resistance to Imipenem [15].

On the other hand, the Gram-negative Pseudomonas aeruginosa was identified in 12.8% of cases as compared to previous reports from Kuwait (17.4% and 17.5%) [13, 15] which appeared higher than those in other geographical regions [43]. Interestingly, Pseudomonas aeruginosa, a multi-drug-resistant organism, has been reported to be highly prevalent in DFI patients from India in many studies [19, 30, 44]. These observations on the prevalence of Pseudomonas aeruginosa suggest regional variability probably due to microbial environments and healthcare practices such as sample collection and processing. Finally, and after dividing the data (DFU classification or infection) according to individual HbA1c levels (controlled or uncontrolled) we could not identify specific trends or associations between HbA1c levels and types of isolates or wound grades, despite the higher rate of men with controlled HbA1c and infected wounds.

Altogether, and in the context of the alarming worldwide increase both in the prevalence of DFI and antimicrobial resistance, our results are in favor of accurate and prompt identification of DFI to ensure the responsible isolates are targeted at earliest with the appropriate antibiotics, thus limiting the unnecessary use of broad-spectrum empirical antibiotics.

Despite the relatively large number of patients and the long period of time covered in our study, some limitations need to be highlighted. One unavoidable pitfall is the fact that our samples are a mixture of swabs and tissue samples that may not give consistent results, in particular with regards to aerobic and anaerobic pathogens as we did not include any condition or analysis of the latter group. In this context, using whole genome sequencing (WGS) approach may provide a more accurate representation of microorganism profiles including non-culturable organisms and a better estimate of the microorganism “load” in DFU. Furthermore, in such studies, only DFU with clinical infection are usually investigated at the microbiological level whereas here we initially included both DFU with and without clinical infection. A standardized procedure will help improve the consistency of microbial quantitation. Indeed, the implementation of guidelines of the International Working Group on the Diabetic Foot for obtaining specimens for culture from patients with DFI has been shown to be have cost-saving potential and provided interesting quality indicators in the global management of DFI [45]. In that study, within a period of 4 years, there was a significant decrease in the number of bacterial species per sample (from 4.1 to 1.6) and in the number of MRSA cases (from 52.2% to 18.9%). Another limitation is the relatively small number of patients in some wound classification groups, which did not allow us to analyze the data to find associations between various pathogens and the wound grading. Finally, our study was retrospective and used only UoT DFU classification system, therefore, a follow-up cohort study with these patients is needed to shed light on potential prediction of clinical outcomes, including wound healing in relation with the type of pathogens, DFU classification, clinical management, and the control of diabetes.

In conclusion, we provided an updated picture of the DFI pattern and showed an improved DFI pattern in comparison to the results in the previous reports from Kuwait and the region. Clinicians should keep up to date on common pathogen patterns in their local area, due to vast regional variability especially when prescribing empirical antibiotics. A combined DFI grading with microbial profile and sensitivity tests will help guide clinicians on the appropriate treatment and wound management.

Supporting information

S1 Table. Minimal data set for study population characteristics.

(XLSX)

Acknowledgments

We would like to thank the staff at the Clinical Laboratory, Dasman Diabetes Institute, for their assistance throughout this study. The authors would like to thank Enago (www.enago.com) for the English language review.

Abbreviation

CAP

College of American Pathologists

DDI

Dasman Diabetes Institute

DFI

Diabetic Foot Infection

DFU

Diabetic Foot Ulcer

MRSA

Methicillin-resistant Staphylococcus aureus

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

No specific funding was requested or provided for this study as all analyses were performed by our staff within our institute using available electronic data.

References

  • 1.Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. : Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999, 22:382–387. 10.2337/diacare.22.3.382 [DOI] [PubMed] [Google Scholar]
  • 2.Reiber GE, Smith DG, Carter J, Fotieo G, Deery HG 2nd, Sangeorzan JA, et al. : A comparison of diabetic foot ulcer patients managed in VHA and non-VHA settings. J Rehabil Res Dev 2001, 38:309–317. [PubMed] [Google Scholar]
  • 3.Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ: Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003, 26:1435–1438. 10.2337/diacare.26.5.1435 [DOI] [PubMed] [Google Scholar]
  • 4.Epicast: EpiCast Report: Diabetic Foot Ulcers—Epidemiology Forecast to 2025. pp. 1–59; 2017:1–59.
  • 5.IDF: IDF Diabetes Atlas. vol. 9th edition pp. 1–176: International Diabetes Federation; 2019:1–176. [Google Scholar]
  • 6.Messenger G, Masoetsa R, Hussain I, Devarajan S, Jahromi M: Diabetic foot ulcer outcomes from a podiatry led tertiary service in Kuwait. Diabet Foot Ankle 2018, 9:1471927 10.1080/2000625X.2018.1471927 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. : High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007, 50:18–25. 10.1007/s00125-006-0491-1 [DOI] [PubMed] [Google Scholar]
  • 8.Jia L, Parker CN, Parker TJ, Kinnear EM, Derhy PH, Alvarado AM, et al. : Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers. PLoS One 2017, 12:e0177916 10.1371/journal.pone.0177916 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, et al. : 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012, 54:e132–173. 10.1093/cid/cis346 [DOI] [PubMed] [Google Scholar]
  • 10.Hicks CW, Selvarajah S, Mathioudakis N, Sherman RE, Hines KF, Black JH 3rd, et al. : Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs. Ann Vasc Surg 2016, 33:149–158. 10.1016/j.avsg.2015.11.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sugandhi P, Prasanth DA: Bacteriological Profile of Diabetic Foot. International Journal of Innovative Research in Science 2014, 3:14688–14692. [Google Scholar]
  • 12.Fair RJ, Tor Y: Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem 2014, 6:25–64. 10.4137/PMC.S14459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA: Bacteriological study of diabetic foot infections. J Diabetes Complications 2005, 19:138–141. 10.1016/j.jdiacomp.2004.06.001 [DOI] [PubMed] [Google Scholar]
  • 14.Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, 45:2819–2828. 10.1128/JCM.00551-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Al Benwan K, Al Mulla A, Rotimi VO: A study of the microbiology of diabetic foot infections in a teaching hospital in Kuwait. J Infect Public Health 2012, 5:1–8. 10.1016/j.jiph.2011.07.004 [DOI] [PubMed] [Google Scholar]
  • 16.Lipsky BA, Itani K, Norden C, Linezolid Diabetic Foot Infections Study G: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004, 38:17–24. 10.1086/380449 [DOI] [PubMed] [Google Scholar]
  • 17.Viswanathan V, Pendsey S, Radhakrishnan C, Rege TD, Ahdal J, Jain R: Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infection in India: A Growing Menace. Int J Low Extrem Wounds 2019:1534734619853668 10.1177/1534734619853668 [DOI] [PubMed] [Google Scholar]
  • 18.Neves JM, Duarte B, Pinto M, Formiga A, Neves J: Diabetic Foot Infection: Causative Pathogens and Empiric Antibiotherapy Considerations-The Experience of a Tertiary Center. Int J Low Extrem Wounds 2019:1534734619839815 10.1177/1534734619839815 [DOI] [PubMed] [Google Scholar]
  • 19.Shankar EM, Mohan V, Premalatha G, Srinivasan RS, Usha AR: Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 2005, 16:567–570. 10.1016/j.ejim.2005.06.016 [DOI] [PubMed] [Google Scholar]
  • 20.Ertugrul BM, Lipsky BA, Ture M, Sakarya S: Risk Factors for Infection with Pseudomonas aeruginosa in Diabetic Foot Infections. J Am Podiatr Med Assoc 2017, 107:483–489. 10.7547/15-167 [DOI] [PubMed] [Google Scholar]
  • 21.Dunyach-Remy C, Ngba Essebe C, Sotto A, Lavigne JP: Staphylococcus aureus Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in Diagnosis. Toxins (Basel) 2016, 8 10.3390/toxins8070209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pereira SG, Moura J, Carvalho E, Empadinhas N: Microbiota of Chronic Diabetic Wounds: Ecology, Impact, and Potential for Innovative Treatment Strategies. Front Microbiol 2017, 8:1791 10.3389/fmicb.2017.01791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lipsky BA: Diabetic foot infections: Current treatment and delaying the ‘post-antibiotic era'. Diabetes Metab Res Rev 2016, 32 Suppl 1:246–253. 10.1002/dmrr.2739 [DOI] [PubMed] [Google Scholar]
  • 24.Armstrong DG, Lavery LA, Harkless LB: Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998, 21:855–859. 10.2337/diacare.21.5.855 [DOI] [PubMed] [Google Scholar]
  • 25.Levine NS, Lindberg RB, Mason AD Jr., Pruitt BA Jr.: The quantitative swab culture and smear: A quick, simple method for determining the number of viable aerobic bacteria on open wounds. J Trauma 1976, 16:89–94. [PubMed] [Google Scholar]
  • 26.Bauer AW, Kirby WM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966, 45:493–496. [PubMed] [Google Scholar]
  • 27.Shakil S, Khan AU: Infected foot ulcers in male and female diabetic patients: a clinico-bioinformative study. Ann Clin Microbiol Antimicrob 2010, 9:2 10.1186/1476-0711-9-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Patil S, Mane R: Bacterial and clinical profile of diabetic foot ulcer using optimal culture techniques. International Journal of Research in Medical Sciences 2017, 5:496–502. [Google Scholar]
  • 29.Mendes JJ, Marques-Costa A, Vilela C, Neves J, Candeias N, Cavaco-Silva P, et al. : Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Pract 2012, 95:153–161. 10.1016/j.diabres.2011.10.001 [DOI] [PubMed] [Google Scholar]
  • 30.Saseedharan S, Sahu M, Chaddha R, Pathrose E, Bal A, Bhalekar P, et al. : Epidemiology of diabetic foot infections in a reference tertiary hospital in India. Braz J Microbiol 2018, 49:401–406. 10.1016/j.bjm.2017.09.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Tascini C, Piaggesi A, Tagliaferri E, Iacopi E, Fondelli S, Tedeschi A, et al. : Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy. Diabetes Res Clin Pract 2011, 94:133–139. 10.1016/j.diabres.2011.07.017 [DOI] [PubMed] [Google Scholar]
  • 32.Tiwari S, Pratyush DD, Dwivedi A, Gupta SK, Rai M, Singh SK: Microbiological and clinical characteristics of diabetic foot infections in northern India. J Infect Dev Ctries 2012, 6:329–332. 10.3855/jidc.1827 [DOI] [PubMed] [Google Scholar]
  • 33.Rahim F, Ullah F, Ishfaq M, Afridi AK, Rahman SU, Rahman H: Frequency Of Common Bacteria And Their Antibiotic Sensitivity Pattern In Diabetics Presenting With Foot Ulcer. J Ayub Med Coll Abbottabad 2016, 28:528–533. [PubMed] [Google Scholar]
  • 34.Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. : Delivery of care to diabetic patients with foot ulcers in daily practice: results of the Eurodiale Study, a prospective cohort study. Diabet Med 2008, 25:700–707. 10.1111/j.1464-5491.2008.02445.x [DOI] [PubMed] [Google Scholar]
  • 35.Xie X, Bao Y, Ni L, Liu D, Niu S, Lin H, et al. : Bacterial Profile and Antibiotic Resistance in Patients with Diabetic Foot Ulcer in Guangzhou, Southern China: Focus on the Differences among Different Wagner’s Grades, IDSA/IWGDF Grades, and Ulcer Types. Int J Endocrinol 2017, 2017:8694903 10.1155/2017/8694903 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Huang Y, Cao Y, Zou M, Luo X, Jiang Y, Xue Y, et al. : A Comparison of Tissue versus Swab Culturing of Infected Diabetic Foot Wounds. Int J Endocrinol 2016, 2016:8198714 10.1155/2016/8198714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Gardiner M, Vicaretti M, Sparks J, Bansal S, Bush S, Liu M, et al. : A longitudinal study of the diabetic skin and wound microbiome. PeerJ 2017, 5:e3543 10.7717/peerj.3543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chambers HF, Deleo FR: Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009, 7:629–641. 10.1038/nrmicro2200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.EARSS: European Antimicrobial Resistance Surveillance System. The Netherlands; 2007.
  • 40.Kinross P, Petersen A, Skov R, Van Hauwermeiren E, Pantosti A, Laurent F, et al. : Livestock-associated meticillin-resistant Staphylococcus aureus (MRSA) among human MRSA isolates, European Union/European Economic Area countries, 2013. Euro Surveill 2017, 22 10.2807/1560-7917.ES.2017.22.44.16-00696 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. : Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207–208. 10.1016/S0140-6736(01)05410-1 [DOI] [PubMed] [Google Scholar]
  • 42.Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, et al. : Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003, 51:186–188. 10.1093/jac/dkg104 [DOI] [PubMed] [Google Scholar]
  • 43.Crouzet J, Lavigne JP, Richard JL, Sotto A, Nimes University Hospital Working Group on the Diabetic F: Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. Int J Infect Dis 2011, 15:e601–610. 10.1016/j.ijid.2011.05.003 [DOI] [PubMed] [Google Scholar]
  • 44.Shanthi M, Sekar U, Kamalanathan A, Sekar B: Detection of New Delhi metallo beta lactamase-1 (NDM-1) carbapenemase in Pseudomonas aeruginosa in a single centre in southern India. Indian J Med Res 2014, 140:546–550. [PMC free article] [PubMed] [Google Scholar]
  • 45.Sotto A, Richard JL, Combescure C, Jourdan N, Schuldiner S, Bouziges N, et al. : Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers. Diabetologia 2010, 53:2249–2255. 10.1007/s00125-010-1828-3 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Rita G Sobral

24 Aug 2020

PONE-D-20-08931

Microbiological profile of diabetic foot ulcers in Kuwait

PLOS ONE

Dear Dr. Tiss,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Several concerns are shared by the reviewers and myself. The design and results of the study need to be further detailed and need to be contextualized with previous work. Also, some conclusions drawn are not fully supported and several observations should me more thoroughly discussed in view of the current global antibiotic resistance situation. Furthermore, the statistical analysis and the interpretation should of the data should be thoroughly revised according to the suggestions of the reviewers. The authors are invited to include further information and the recommended controls and to provide a revised manuscript and a point-by-point response to each comment raised by the reviewers.

Please submit your revised manuscript by Oct 08 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Rita G. Sobral, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: No

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: While the topic of the manuscript is indeed interesting and relevant, I have a set of concerns/queries, as outlined below:

- The first cited reference is a previous study published by part of the authors also involved in the current manuscript: “Messenger G, Masoetsa R, Hussain I, Devarajan S, Jahromi M: Diabetic foot ulcer outcomes from a podiatry led tertiary service in Kuwait. Diabet Foot Ankle 2018, 9:1471927.” Much of the same methodology was used, but the first paper looked at different outcomes, in the time span 2014-2016. The following microbiology data is reported in this previous article: “Microbiology samples were collected from 150 DFUs, of which nearly 40% were positive for bacterial growth. The most common microorganisms were Gram-negatives (16%), and 11 (3%) new cases of Methicillin-resistant Staphylococcus aureus (MRSA) were identified.” I find it hard to understand why a new paper would be needed, and why publish these two analyses as two separate manuscripts.

- Line 24: The phrasing should be revised, since it is an overstatement to say that the study’s aim was to characterize DFU “within Kuwait”. The same can be said for the conclusions on line 40 “patterns in Kuwait”, and for the manuscript’s title. This data reflects, at best, the population attending the DDI center in Kuwait in the study time span.

- Furthermore, this study population attending the DDI center should be clearly defined on line 93, where a brief description of the hospital is first given.

- Line 26: A brief statement regarding the criteria used for selecting patients for the study should be included here. For example: all consecutive patients attending the Institute within a specific time span.

- Lines 38 and 39: It would be easier to follow the numbers if the same order is used for reporting. In these phrases female cases are reported first and then male cases first.

- Line 41: “the observed regional variability of DFI pathogens” – this study has not looked at regional variability specifically, only the discussion section provides a comparison with different regions/countries. However, this comparison cannot truly reflect a regional variability, since differences in methodology can be reasonably expected.

- Line 42: Since this was not a study of wound healing time/quality, or of clinical outcomes, the following phrase is not a direct conclusion of the study: “to enhance wound healing and improve clinical outcomes.”

- Line 49: “The lifetime risk of developing a DFU is estimated to be 12 to 25% [1, 2].” This phrase requires clarification. Are the findings from literature reported here valid only for patients with diabetes? Or for the general population? Furthermore, it is not clear from which literature reference this information was derived, since the reference quoted here (#1) cites the following different information, for the same reported percentages, and further citing another literature sources: “Diabetic foot ulcers (DFUs) continue to be a leading cause of non-traumatic lower limb amputation [1], with an estimated lifetime risk of 12–25% [2–4].” Citations should generally point towards the initial source and it should be checked that the intended meaning is portrayed.

- Line 53: “Despite the fact that the prevalence of diabetes in Kuwait is ranked among the highest worldwide” – how high?

- Line 64: Please recheck italicizing and capitalization. All bacterial genus and species names should be written in italic font, whereas “spp.” or “species” should not. Genus names should be capitalized, while species names should not.

- Lines 72-73: Depth of the wound and sampling technique can also be involved.

- Line 74: The term “colonizers” should be used only when talking about colonization, i.e., not infection.

- Line 100 and ethics statement: The Declaration of Helsinki generally refers to the rights of subjects in interventional clinical trials. Also, a statement should be included regarding the waiver of informed consent by an ethics committee.

- Line 128: CAP should be defined at the first use in the text.

- Line 149: Check spelling and italicization: Acinitobacter, etc.

- Line 158: Check producer for this SPSS version. It should be: IBM Corp., Armonk, NY, USA)’.

- Line 159: Student’s t test is only appropriate for variables with parametric distribution. Was variable distribution checked for all continuous variables?

- Lines 205, 232, 308 and other occurrences: By Staphylococcus aureus, are the authors referring to MSSA?

- Lines 226-229: Check the use of italic font.

- Line 243: Correlation analysis is only applicable for continuous variables. An “association” should be discussed instead.

- Lines 245 and all antimicrobial names: Check capitalization.

- Line 248: The 97.5% susceptibility to linezolid should be discussed as this is an important, worrisome finding.

- Line 252: The decreased susceptibility to carbapenems should be discussed.

- Figure 1: “Controlled male/female” and “Uncontrolled male/female” sounds a bit awkward and should be revised. Furthermore, a figure legend should clarify that this term refers to glycemic control and the values for control should be stated here, i.e., 6.5.

- Full statistical comparisons should be included in the relevant tables and only discussed in the text.

- Table 1 is hard to follow.

- Table 2, Table S1 and analysis in the manuscript text: Please revise the definition of “controlled” and “uncontrolled”. At the current moment a patient with 6.5 does not fit into any of these categories. Please revise and recalculate.

- Table S1: This table is not very relevant. Furthermore, in the A3 rows, how can a “controlled” patient have an HBa1c level > 10?

- Table 3 is not needed, as much of this information is already presented in the text.

- Table 4: Please revise the use of italic font and spelling of some of the bacterial names.

- Table 5 is a bit hard to follow because of the different column names in the first and second half of the table.

- Table 5: Data on cefoxitin screening for S. aureus should also be included.

- The references used for comparison in the Discussion section should overall be read more carefully, to avoid misinterpretation of the data when citing their results.

- Line 271: These are not “the first estimates”, as the authors have already published data on this topic, as mentioned above.

- Lines 286-289: When discussing mono- vs poly-microbial infection, it would be important to look at the sampling and processing techniques in each study, otherwise the overall numbers cannot be compared.

- Line 340: It is not clear what this phrase refers to: “the most persistent pathogens in healthcare facilities worldwide”.

- Lines 341-344: The authors state that: “The presence of MRSA in our study was only 5.0% of the total isolates detected. This rate is much lower than European statistics. Recently, The European Centre for Disease Prevention and Control (ECDC) reported that the prevalence of MRSA decreased across Europe from 19.6% in 2014 to 16.9% in 2017 [43].” However, these numbers cannot be compared, since the cited report reflects the percentage of MRSA isolates from the total number of S. aureus isolates, while the percentage reported in the current manuscript does not.

- Line 345: Reduction compared to what?

- Line 346: Improvement compared to what/when?

- Line 354: What differences in healthcare practice?

- The reference list is quite long for an original article, and many of the references included here are either outdated, or not directly relevant to the current study.

- Data availability statement: “All generated data and resources are reported in this manuscript and there is no other data to be provided.” The source dataset should also be made available.

- English language is overall ok, but it should be revised to address occasional mistakes or errors.

Reviewer #2: I would like to thank the authors for their paper. The topic of diabetic foot ulcers and the microbiological profiles will be of great interest to readers. While the paper is well-written, I believe there is a major methodological error in this study, which inhibits the ability to draw valid conclusions. Please refer below to my full list of thoughts, comments, suggestions, and questions:

• Lines 148-156: Materials and Methods: Antimicrobial Susceptibility Testing- Please include the antibiotic list and concentrations used. Adding the concentrations of discs used will ensure reproducibility.

• Line 208: Results: Microbial Isolate Etiologies in DFUs with clinical infection- The authors indicate that to characterize the microbiological profile they only analyzed “clinically infected wounds”. The “clinically uninfected” could essentially have served as the control group. When characterizing microbiological profiles, it is very essential to have a control group that would help understand the “baseline microbiological composition”, and thus would help make valid conclusions about what truly is the microbiological composition of the diseased state (in this case clinically infected samples). Not characterizing the microbiological composition of a control is a major methodological error of this study.

• Line 244: Results: Antimicrobial susceptibility pattern- Please switch the outcome to % resistant instead of %sensitive/susceptible. Since the authors report % resistance for Acinetobacter and Enterobacter species, I believe it would be beneficial if the authors continue to report the results of the antimicrobial resistance patterns as % resistant.

• Discussion: Please include the significance of the antimicrobial resistance testing results in the discussion and what this would mean for the clinical management of DFUs and DFIs.

• Discussion: I would also recommend the authors to include another limitation of the study in their discussion. Since the authors have employed a culture-based approach to characterize microorganisms, some microorganisms might be unculturable. Using whole genome sequencing (WGS) to characterize microbiological profiles may provide a more accurate representation of microorganism profiles. Not only will WGS characterize non-culturable organisms, but the number of reads can be used to estimate the “load” of microorganisms in DFUs.

• Line 557 Table S1: I would recommend the authors label each stage and grade and depth for clarity. For instance, label A0 with “Pre- or post-ulcerative lesion completely epithelialized”, A1 with “Superficial wound not involving tendon, capsule or bone” so on and so forth.

Reviewer #3: Microbiological profile of diabetic foot ulcers in Kuwait

This paper describes a retrospective study of the microbiology profile diabetic foot ulcers in Kuwait. It adds little if any novel findings to the field; however, such is the nature of studies of this type and that should not preclude publication.

Overall, the paper is well written and well-presented. However, there are several major and minor revisions which we need to be addressed before publication.

Major revisions

1. It would be useful if the authors could present a breakdown of the number of patients whose ulcers (x/260) or infections (x/253) were investigated using either swab or tissue sample collection.

The authors are correct in their discussion when they highlight that this is a limitation of this work. It may also reflect the high proportion of coagulase-negative staphylococcus identified in table 4, and the potential for contaminating skin flora to be detected by superficial swabs should be highlighted in the discussion.

2. This paper should include a clear breakdown of the number of bacterial isolates detected from the 253 infected patients, regardless of their Texas grade, and the frequency with which each bacterial species was identified. This should come in table format.

Minor revisions

1. There are multiple instances in this paper where the abbreviation for diabetic foot infection or diabetic foot ulcer is used incorrectly. The authors need to carefully check that every time they have used a three-letter acronym (DFU vs. DFI) they have used the correct one. Examples of lines where attention is required include:

31-‘DFU infections’

80-‘microbes isolated from DFIs from a different DFUs using the University of Texas…’ This needs clarifying, I think you mean provide power microbes isolated from DFI’s from different ulcer grades.

82-should be DFI pathogens

83-should be the microbial profile of DFIs

112

211-an infected DFU is a DFI

These examples are not exhaustive, there may be others.

2. Throughout the manuscript you have used sex and gender interchangeably. Please use sex throughout.

3. Please define the abbreviation CAP-line 128

4. There is a formatting issue on lines 192 and 201-please correct. Also on these lines, please insert ‘df’ if you refer to degrees of freedom in the parentheses. At it’s first use degrees of freedom should be defined as ‘df’.

5. Line 193-please write ‘years’ in full

6. Line 202. If you have used an ‘F test’ please also include this in your methods.

7. Line 209-please remind the reader of the number of clinic infected wounds to which you are referring – e.g. (n = x)

8. Throughout the manuscript you have been inconsistent in your spacing of figures. For example, n=x vs. n = x. Please choose one format and stick with it throughout.

9. Line 248 please insert ‘was’ between ‘but less’

10. Line 272, should read ‘contained twice as many men as women’

11. Line 290, the claim that most diabetic foot infections are ‘dominated’ by Gram-negative strains is based on five references here. All these references come from papers published in India or China. You cannot make a statement about ‘most reports’ easier handfuls of papers from very limited geographical sources. As it happens, certainly in Western Europe and the United States, it is most often gram-positive cocci which predominate in these infections. I suggest removing this sentence.

12. Line 305, extra space has been inserted

13. line 339, you mean species not strain.

14. Table 1, please sort out formatting, move the heading ‘controlled’ up

15. Table 2, please clarify for the reader that you mean Texas wound grading. This needs to be clarified in both the legend and the table.

16. Figure 2, do you mean species instead of strain?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Sanjana Mukherjee

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Rita G Sobral

8 Dec 2020

Microbiological profile of diabetic foot ulcers in Kuwait

PONE-D-20-08931R1

Dear Dr. Tiss,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Rita G. Sobral, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #4: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #4: No

Acceptance letter

Rita G Sobral

11 Dec 2020

PONE-D-20-08931R1

Microbiological profile of diabetic foot ulcers in Kuwait

Dear Dr. Tiss:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Rita G. Sobral

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Minimal data set for study population characteristics.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES